Hillman Tatiana
Biotechnology, LAL4Bsynbiotics L.L.C, Los Angeles, CA, United States.
Front Oncol. 2023 Jun 14;13:1194350. doi: 10.3389/fonc.2023.1194350. eCollection 2023.
Colon cancer is one of the leading causes of cancer in the United States. Colon cancer develops from the many gene mutations found in the genomes of colon cancer cells. Long non-coding RNAs (lncRNAs) can cause the development and progression of many cancers, including colon cancer. LncRNAs have been and could be corrected through the gene-editing technology of the clustered repeats of the clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease 9 (CRISPR/Cas9) system to reduce the proliferation of cancer cells in the colon. However, many current delivery systems for transporting CRISPR/Cas9-based therapeutics need more safety and efficiency. CRISPR/Cas9-based therapeutics require a safe and effective delivery system to more directly and specifically target cancer cells present in the colon. This review will present pertinent evidence for the increased efficiency and safety of using plant-derived exosome-like nanoparticles as nanocarriers for delivering CRISPR/Cas9-based therapeutics to target colon cancer cells directly.
结肠癌是美国癌症的主要病因之一。结肠癌由结肠癌细胞基因组中发现的多种基因突变发展而来。长链非编码RNA（lncRNAs）可导致包括结肠癌在内的多种癌症的发生和发展。通过成簇规律间隔短回文重复序列（CRISPR）相关核酸酶9（CRISPR/Cas9）系统的成簇重复序列的基因编辑技术，lncRNAs已经并且可以得到纠正，以减少结肠癌细胞的增殖。然而，目前许多用于运输基于CRISPR/Cas9的疗法的递送系统需要更高的安全性和效率。基于CRISPR/Cas9的疗法需要一个安全有效的递送系统，以便更直接、更特异性地靶向存在于结肠中的癌细胞。本综述将提供相关证据，证明使用植物来源的外泌体样纳米颗粒作为纳米载体直接递送基于CRISPR/Cas9的疗法来靶向结肠癌细胞，可提高效率和安全性。
